Prolia (Denosumab) Mental Health and Mood Impact: What the Evidence Shows

Does Prolia cause depression or anxiety?

Neither appears in the label's adverse-reaction table for postmenopausal osteoporosis. That section describes a 3-year trial [2] in which 3,886 postmenopausal women received Prolia and 3,876 received placebo; all were instructed to take at least 1,000 mg calcium and 400 IU vitamin D daily [1].

The label's table lists common adverse reactions reported more often with Prolia than placebo. It includes back pain (34.7% vs 34.6%), pain in extremity (11.7% vs 11.1%), musculoskeletal pain (7.6% vs 7.5%), hypercholesterolemia (7.2% vs 6.1%) and cystitis (5.9% vs 5.8%); rash or eczema was also more frequent with Prolia [1]. Depression and anxiety are not in that table or in the label's most-common list [1]. That does not show whether either symptom occurred or how often [1].

What low calcium can do

Severe low blood calcium is a documented Prolia risk, and the FDA lists confusion, seizures, irregular heart rhythm, fainting and uncontrolled muscle spasms among its possible symptoms [1][3]. The label says pre-existing hypocalcemia must be corrected before starting and instructs all patients to take calcium 1,000 mg and at least 400 IU vitamin D daily [1]. In the fracture trial, serum calcium below 8.5 mg/dL at any visit occurred in 1.7% of women on Prolia versus 0.4% on placebo, with the lowest level about 10 days after dosing in people with normal kidney function [1].

The boxed warning covers advanced kidney disease. In female dialysis-dependent Medicare patients, the FDA reported a 12-week cumulative incidence of severe hypocalcemia of 41.1% with denosumab (n=1,523) versus 2.0% with oral bisphosphonates (n=1,281) [3]. In patients with advanced kidney disease, most cases began 2 to 10 weeks after each injection, with the greatest risk in weeks 2 to 5 [3].

What about stopping Prolia?

The label's discontinuation guidance concerns bone. After Prolia is stopped, fracture risk rises, including multiple vertebral fractures, with new vertebral fractures reported as early as 7 months after the last dose; the label says patients who discontinue should be transitioned to another antiresorptive therapy [1].